ClinicalTrials.gg

Program

anzutresgene autoleucel

Also written as “IMA203”, “IMA203 Product” and “IMA203 product- flat dose”.

Its studies are mostly in Melanoma, Cutaneous Malignant · Neoplasms · Melanoma, led by Immatics US.

Furthest: phase 3, since Dec 11, 20243 company-led studies, 3 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immatics US33 open or runningphase 3since Dec 11, 2024Sep 25, 2018Jan 2028phase 3 · NCT06743126

Also a collaborator on its studies: Moderna.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 25, 2018First study: phase 2 study in NeoplasmsFirst studyNCT03686124 · 375 planned · United States, Germany
  2. Dec 11, 2024Phase 3 study in Melanoma, Cutaneous MalignantNCT06743126 · 450 planned · United States, Canada, France and more
  3. Apr 19, 2025Phase 1 study in MelanomaNCT06946225 · 15 planned · United States

Ahead

  1. Jan 2028Primary completion: phase 3 study in Melanoma, Cutaneous MalignantNCT06743126
  2. Dec 2028Primary completion: phase 2 study in NeoplasmsNCT03686124
  3. Aug 2029Primary completion: phase 1 study in MelanomaNCT06946225

TargetBeta

PRAME →read by rule
“A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), ”NCIt, by rule

Other programs on PRAME

ProgramCompanyFurthest phaseStudies
PRAME mRNA Vaccine mRNA-4203ruleImmatics USphase 11
Autologous Anti-PRAME TCR-expressing T-cells OPB-201ruleoutpace-bio-incphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06946225Melanoma · United States1RecruitingAug 202915
NCT06743126Melanoma, Cutaneous Malignant · United States, Canada, France and more3RecruitingJan 2028450
NCT03686124Neoplasms · United States, Germany2RecruitingDec 2028375

How it is read

Names in the registry

  • “IMA203”, 2 entries
  • “IMA203 Product”, 1 entry
  • “IMA203 product- flat dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.